BALPHARMA.BOBALPHARMA.BOBSE

Revenue (LTM)

$3.0B

-10.7% YoY

Net Income (LTM)

$72M

-2.4% YoY

Free Cash Flow

$-146M

Revenue CAGR (5Y)

+12.1%

Marginsdeclining

FCFTurned negative

Profitable

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Revenue	2,469	2,812↑13.9%	3,042↑8.2%	3,392↑11.5%	3,031↓10.7%
Gross Profit	993	1,115↑12.3%	1,255↑12.5%	770↓38.6%	730↓5.2%
Operating Income	141	149↑6.1%	177↑18.8%	215↑21.1%	198↓7.8%
Net Income	47	56↑18.3%	26↓54.2%	74↑187.4%	72↓2.4%
EBITDA	258	240↓7.0%	245↑2.2%	320↑30.7%	318↓0.8%
EPS Diluted	3.34	3.79↑13.5%	1.64↓56.7%	4.68↑185.4%	4.56↓2.6%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Cash & Equivalents	10	11↑8.7%	15↑33.6%	42↑182.1%	81↑91.9%
Total Current Assets	1,641	1,846↑12.4%	2,282↑23.6%	2,341↑2.6%	2,349↑0.3%
Total Assets	2,401	2,605↑8.5%	3,132↑20.2%	3,195↑2.0%	3,357↑5.1%
Total Current Liabilities	1,525	1,656↑8.6%	2,093↑26.4%	2,030↓3.0%	2,195↑8.1%
Total Liabilities	1,867	2,020↑8.2%	2,495↑23.5%	2,503↑0.3%	2,583↑3.2%
Total Equity	536	586↑9.4%	638↑8.8%	693↑8.6%	774↑11.7%
Total Debt	1,119	1,067↓4.7%	1,331↑24.8%	1,423↑6.9%	1,504↑5.7%
Net Debt	1,109	1,055↓4.9%	1,295↑22.7%	1,381↑6.6%	1,424↑3.1%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Operating Cash Flow	218	277↑27.2%	-18↓106.7%	228↑1337.1%	42↓81.4%
Capital Expenditure	-34	-85↓148.1%	-146↓72.9%	-110↑25.0%	-188↓71.1%
Free Cash Flow	184	192↑4.7%	-165↓185.7%	118↑171.7%	-146↓223.1%
Stock-Based Comp	0	9	0	0	0
Net Change in Cash	2	1↓45.8%	4↑319.3%	27↑623.5%	37↑37.9%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance